000294417 001__ 294417
000294417 005__ 20241107161550.0
000294417 0247_ $$2doi$$a10.1038/s41467-020-18388-7
000294417 0247_ $$2pmid$$apmid:32934208
000294417 0247_ $$2pmc$$apmc:PMC7492191
000294417 037__ $$aDKFZ-2024-02246
000294417 041__ $$aEnglish
000294417 082__ $$a500
000294417 1001_ $$aManzella, Gabriele$$b0
000294417 245__ $$aPhenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity.
000294417 260__ $$a[London]$$bNature Publishing Group UK$$c2020
000294417 3367_ $$2DRIVER$$aarticle
000294417 3367_ $$2DataCite$$aOutput Types/Journal article
000294417 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730990782_25079
000294417 3367_ $$2BibTeX$$aARTICLE
000294417 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294417 3367_ $$00$$2EndNote$$aJournal Article
000294417 520__ $$aCancer therapy is currently shifting from broadly used cytotoxic drugs to patient-specific precision therapies. Druggable driver oncogenes, identified by molecular analyses, are present in only a subset of patients. Functional profiling of primary tumor cells could circumvent these limitations, but suitable platforms are unavailable for most cancer entities. Here, we describe an in vitro drug profiling platform for rhabdomyosarcoma (RMS), using a living biobank composed of twenty RMS patient-derived xenografts (PDX) for high-throughput drug testing. Optimized in vitro conditions preserve phenotypic and molecular characteristics of primary PDX cells and are compatible with propagation of cells directly isolated from patient tumors. Besides a heterogeneous spectrum of responses of largely patient-specific vulnerabilities, profiling with a large drug library reveals a strong sensitivity towards AKT inhibitors in a subgroup of RMS. Overall, our study highlights the feasibility of in vitro drug profiling of primary RMS for patient-specific treatment selection in a co-clinical setting.
000294417 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294417 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000294417 650_7 $$2NLM Chemicals$$aProtein Kinase Inhibitors
000294417 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aProto-Oncogene Proteins c-akt
000294417 650_2 $$2MeSH$$aAnimals
000294417 650_2 $$2MeSH$$aAntineoplastic Agents: pharmacology
000294417 650_2 $$2MeSH$$aBiological Specimen Banks
000294417 650_2 $$2MeSH$$aDrug Screening Assays, Antitumor: methods
000294417 650_2 $$2MeSH$$aGene Expression Profiling
000294417 650_2 $$2MeSH$$aHumans
000294417 650_2 $$2MeSH$$aPhenotype
000294417 650_2 $$2MeSH$$aProtein Kinase Inhibitors
000294417 650_2 $$2MeSH$$aProto-Oncogene Proteins c-akt: antagonists & inhibitors
000294417 650_2 $$2MeSH$$aProto-Oncogene Proteins c-akt: genetics
000294417 650_2 $$2MeSH$$aProto-Oncogene Proteins c-akt: metabolism
000294417 650_2 $$2MeSH$$aRhabdomyosarcoma: drug therapy
000294417 650_2 $$2MeSH$$aRhabdomyosarcoma: genetics
000294417 650_2 $$2MeSH$$aRhabdomyosarcoma: metabolism
000294417 650_2 $$2MeSH$$aTumor Cells, Cultured: drug effects
000294417 650_2 $$2MeSH$$aXenograft Model Antitumor Assays
000294417 7001_ $$aSchreck, Leonie D$$b1
000294417 7001_ $$aBreunis, Willemijn B$$b2
000294417 7001_ $$aMolenaar, Jan$$b3
000294417 7001_ $$aMerks, Hans$$b4
000294417 7001_ $$aBarr, Frederic G$$b5
000294417 7001_ $$aSun, Wenyue$$b6
000294417 7001_ $$aRömmele, Michaela$$b7
000294417 7001_ $$aZhang, Luduo$$b8
000294417 7001_ $$aTchinda, Joelle$$b9
000294417 7001_ $$aNgo, Quy A$$b10
000294417 7001_ $$00000-0002-9633-4042$$aBode, Peter$$b11
000294417 7001_ $$00000-0002-8730-2276$$aDelattre, Olivier$$b12
000294417 7001_ $$00000-0002-7118-7859$$aSurdez, Didier$$b13
000294417 7001_ $$00000-0002-3509-4794$$aRekhi, Bharat$$b14
000294417 7001_ $$aNiggli, Felix K$$b15
000294417 7001_ $$00000-0001-5988-2915$$aSchäfer, Beat W$$b16
000294417 7001_ $$aWachtel, Marco$$b17
000294417 773__ $$0PERI:(DE-600)2553671-0$$a10.1038/s41467-020-18388-7$$gVol. 11, no. 1, p. 4629$$n1$$p4629$$tNature Communications$$v11$$x2041-1723$$y2020
000294417 8564_ $$uhttps://inrepo02.dkfz.de/record/294417/files/s41467-020-18388-7.pdf
000294417 8564_ $$uhttps://inrepo02.dkfz.de/record/294417/files/s41467-020-18388-7.pdf?subformat=pdfa$$xpdfa
000294417 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT COMMUN : 2022$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:09:09Z
000294417 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:09:09Z
000294417 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2023-05-02T09:09:09Z
000294417 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-05-02T09:09:09Z
000294417 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)1060$$2StatID$$aDBCoverage$$bCurrent Contents - Agriculture, Biology and Environmental Sciences$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNAT COMMUN : 2022$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-29
000294417 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-29
000294417 980__ $$ajournal
000294417 980__ $$aEDITORS
000294417 980__ $$aI:(DE-He78)W510-20160331
000294417 980__ $$aI:(DE-He78)W500-20160331
000294417 9801_ $$aEXTERN4VITA